Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)

References

• Bloechl-DaumBDeusonRRMavrosPDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol2006244472447816983116
   PubMed Web of Science ®Google Scholar
• CohenLde MoorCAEisenbergPChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• NavariRMManagement of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agentsDrugs20137324926223404093
   PubMed Web of Science ®Google Scholar
• NavariRMPalonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancerFuture Oncol2010610741084
   Web of Science ®Google Scholar
• NavariRMThe current status of the use of palonosetronExpert Opin Pharmacother2013141281128423647207
   PubMed Web of Science ®Google Scholar
• CurranMPRobinsonDMAprepitant: a review of its use in the prevention of nausea and vomitingDrugs2009691853185819719336
   PubMed Web of Science ®Google Scholar
• NavariRMOlanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomitingEur J Pharmcol2014722180186
   PubMed Web of Science ®Google Scholar
• TanLLiuJLiuXClinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomitingJ Exp Clin Cancer Res2009281719126230
   PubMed Web of Science ®Google Scholar
• NavariRMGraySEKerrACOlanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trialJ Support Oncol2011918819522024310
   PubMedGoogle Scholar
• NavariRMTreatment of chemotherapy-induced nauseaCommunity Oncol201292026
   Google Scholar
• SternRMKochKLAndrewsPLRNausea: Mechanisms and ManagementNew York, NYOxford University Press2011
   Google Scholar
• RoilaFHerrstedtJAaproMGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnn Oncol201021523224319675093
   PubMedGoogle Scholar
• BaschEPrestrudAAHeskethPJAntiemetic American Society Clinical Oncology clinical practice guideline updateJ Clin Oncol2011294189419821947834
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology version 2. 2014; Anti-emesisNational Comprehensive Cancer Network (NCCN) [online] Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdfAccessed July 8, 2014
   Google Scholar
• NavariRMPalonosetron for the treatment of chemotherapy-induced nausea and vomitingExpert Opin Pharmacother201415172599260825323946
   PubMed Web of Science ®Google Scholar
• EglerRMLeeCHSmithWPharmacologic characterization of RS 25259-197, a novel and selective 5HT3 receptor antagonist in vivoBr J Pharmacol19951148608667773547
   PubMed Web of Science ®Google Scholar
• EisenbergPMacKintoshFRRitchPEfficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical studyAnn Oncol20041533033714760130
   PubMed Web of Science ®Google Scholar
• RojasCThomasAGAltJPalonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor functionEur J Pharmacol201062619319919836386
   PubMed Web of Science ®Google Scholar
• BotrelTClarkOClarkLEfficacy of palonosetron compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysisSupport Care Cancer20111982383220495832
   PubMed Web of Science ®Google Scholar
• SchwartzbergLBarbourSYMorrowGRPooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomitingSupport Care Cancer20142246947724141698
   PubMed Web of Science ®Google Scholar
• PopovicMWarrDGDeAngelisCEfficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trialsSupport Care Cancer2014221485149724414996
   PubMed Web of Science ®Google Scholar
• BocciaRGrunbergSFranco-GonzalesEEfficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase III trialSupport Care Cancer2013441453146023354552
   PubMedGoogle Scholar
• DiemunschPGrelotLPotential of substance P antagonists as antiemeticsDrugs20006053354611030465
   PubMed Web of Science ®Google Scholar
• SankhalaKKPandyaDMSarantopoulosJPrevention of chemotherapy induced nausea and vomiting: a focus on aprepitantExp Opin Drug Metab Toxicol20091216071614
   Google Scholar
• NavariRMPathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agentsJ Support Oncol200318910315352652
   PubMedGoogle Scholar
• HeskethPJGrunbergSMHerrstedtJCombined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseSupport Care Cancer20061435436016450086
   PubMed Web of Science ®Google Scholar
• WarrDGGrunbergSMGrallaRJThe oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from two randomized, double-blind, placebo controlled trialsEur J Cancer20054191278128515939263
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol2005232822283015837996
   PubMed Web of Science ®Google Scholar
• GroteTHajdenbergJCartnellACombination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitantJ Support Oncol20064840340817004515
   PubMedGoogle Scholar
• NavariRMFosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomitingExp Opin Investig Drugs20071619771985
   PubMed Web of Science ®Google Scholar
• LasseterKCGambaleJJinBTolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjectsJ Clin Pharmacol20074783484017525168
   PubMed Web of Science ®Google Scholar
• GrunbergSChuaDMaruASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASEJ Clin Oncol201129111495150121383291
   PubMed Web of Science ®Google Scholar
• PomaAChristensenJPertikisHRolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 susbstrateSupport Care Cancer201321S154 Abstract 441
   Google Scholar
• RapoportBLPomaAHedleyMLMartelRENavariRMPhase III trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC) [abstract]J Clin Oncol201432Suppl 59638
   Google Scholar
• SchnadigIDModianoMRPomaAHedleyMLMartelRESchwartzbergLSPhase III trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC) [abstract]J Clin Oncol201432Suppl 59633
   Google Scholar
• UrbanLPomaADaqrdenoMMMartelRESafety of rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) [abstract]J Clin Oncol201432Suppl 59636
   Google Scholar
• RizziACampiBCamardaVIn vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist NetupitantPeptides201237869722732666
   PubMed Web of Science ®Google Scholar
• RossiGTilkolaSORudengrenCA positron emission tomography study to assess the degree of neurokinin-1 receptor occupancy in the human brain after single doses of netupitant to healthy male subjects [abstract]J Clin Oncol201230Suppl9054
   Google Scholar
• SpinelliTCalcagneliSGiulianoCNetupitant PET Imaging and ADME Studies in HumansJ Clin Pharm20145497108
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteDrug Dictionary Available from: http://www.cancer.gov/drugdictionaryAccessed October 15, 2014
   Google Scholar
• RojasCSlusherBSPharmacological mechanisms of 5-HT3 tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomitingEur J Pharmacol20126841722425650
   PubMed Web of Science ®Google Scholar
• StathisMPietraCRojasCSlusherBSInhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effectsEur J Pharmacol2012689253022683863
   PubMed Web of Science ®Google Scholar
• ThomasAGStathisMRojasCSlusherBSNetupitant and palonosetron trigger NK-1 receptor internalization in NG108-15 cellsExp Brain Res201423282637264424969614
   PubMed Web of Science ®Google Scholar
• RojasCRajeMTsukamotoTSlusherBSMolecular mechanisms of 5-HT3 and NK-1 receptor antagonists in prevention of emesisEur J Pharmacol2014722263724184669
   PubMed Web of Science ®Google Scholar
• HeskethPJRossiGRizziGEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal studyAnn Oncol2014251340134624608196
   PubMed Web of Science ®Google Scholar
• AaproMRugoHRossiGA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnn Oncol2014251328133324603643
   PubMed Web of Science ®Google Scholar
• AaproMKarthausMSchwartzbergLSPhase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy cycles [abstract]J Clin Oncol201432Suppl 59502
   Google Scholar
• GrallaRJBosnjakSMHontsaAA phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapyAnn Oncol2014251333133924631949
   PubMed Web of Science ®Google Scholar
• SchwartzbergLAaproMHeskethPJdo NK-1 receptor antagonists contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK-1 receptor antagonist plus a 5-HT3 receptor antagonist from pivotal trialsSupport Care Cancer201422S107 Abstract 161
   Google Scholar
• US Food and Drug AdministrationFDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy [press release]Silver Springs, MDUS Food and Drug Administration10102014 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncementsAccessed October 10, 2014
   Google Scholar